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Abstract:  
Background: The value of MS registry information is increasingly recognised and a structured 
description of this data will facilitate analysis and comparisons of the data.  
Objective: The overall aim was to create an overview of the MS registry landscape by updating and 
expanding a previous study of identifying and describing MS registry data currently collected in 
Europe. 
Methods: We approached identified MS registries and requested their participation in the study by 
filling in an extensive survey.   
Results: Nineteen surveys were completed and returned. The main aim and focus of the different 
registries vary considerably as does the number of MS patients and inclusion criteria. Most registries 
collect data within common general categories although there are more pronounced differences 
regarding specific subcategories.  
Conclusion: Information on data collected by European MS registries is essential for large 
international projects. Such efforts involve large amounts of harmonised data and depend on 
functional technical solutions as well as regulatory requirements to allow individual registries to 
contribute data in a manner, which complies with local and national requirements. 
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Introduction:  
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central 
nervous system which affects 2.5 million people worldwide (1). There are significant geographical 
differences with the highest prevalence occurring in Northern Europe and North America (over 
100/100,000) as compared to 2/100,000 in Japan (2, 3). MS patients are typically diagnosed between 
the ages of 20 and 50 years (4) and will in most cases be expected to live for a long time with MS (5). 
Although the treatment options have improved dramatically over the past decades, health care 
regulations and treatment strategies vary significantly between different countries (6). 
The value of MS registries for MS patients, health care providers and regulators is becoming 
increasingly recognised (7).  The collection of patient data into a registry can benefit the patients by 
enabling the clinician to prospectively follow the individual patient concerning disease progression, 
treatment response and side effects, and other parameters including patient reported outcomes 
(PRO) measures (8). From a societal viewpoint there are also many advantages of using data from MS 
registries, especially within areas of epidemiology and treatment studies, such as post marketing 
effectiveness, comparative  or post-authorisation safety studies (9). This was recognised by 
regulatory bodies in the EU resulting in the first EMA-Workshop on MS-Registries in July 2017 in 
London (10). Therefore  it is important to improve and promote the collection of safety data by MS 
registries as this might provide an opportunity for the MS registries to replace the typical drug 
specific post-authorization safety studies (11). 
National or regional MS registries could represent the foundation on which to develop larger scale 
important asset of data for different stakeholders (12). If the appropriate study designs and a 
common data set can be agreed upon, MS registries may offer an excellent source of data in order to 
ultimately address the topic of how to provide the best and most cost effective care model for 
persons with MS (PwMS) and to monitor treatments safety. Sub-group registries such as the German 
registry on pregnant women with MS can provide further valuable insights (13).  
In our previous survey (14), 13 European MS registries were described. The current study was 
performed to update and expand the knowledge of the MS registry data and includes 19 MS 
registries, all based in Europe, with the exception of the international MSBase (15). 
 
Materials and Methods: 
Identification of MS registries and databases: We approached the 13 MS registries that participated 
in the 2014 study by Flachenecker et al (14) and received completed survey responses from 12 of 
them. We contacted a further 12 MS registries which had been identified by the European Multiple 
Sclerosis Platform (EMSP) (16) and received completed surveys from eight of them. Subsequently, 
the results of the Liguria MS register survey were incorporated with those of the Italian MS register, 
reducing the total number of registries to 19.  
Development of survey: The survey was based on the previous questionnaire used in the 2014 study 
(14) and further modified with additions from the MS Registry Advisory Board pre-meeting survey 
(S1) as well as questions considered relevant by the authors for collecting information on registry 
data. The survey included questions on organisational aspects, background/purpose, inclusion 
criteria, documentation process, data collection, quality control, governance, and the status of the 
registry as of January 31, 2017. The survey questions on data collection incorporated personal data, 
clinical categories, patient derived measures and additional categories including co-morbidities, 
socioeconomic and societal services and healthcare utilization. The contact persons of the registries 
were asked to report if data is collected (yes or no). The registries were also asked to indicate if filling 
in data is mandatory or optional as well as to provide data counts on the different variables, if 
available. The original questionnaire has been included as supplementary information (S2). 
Distribution of survey: Representatives of the MS registries were contacted by email enclosing a 
cover letter and the survey. The senders of the letter were representatives of Karolinska Institutet 
(AG and JH), Swedish MS registry (JH), EMSP (CT), MS Registry DMSG (AS), OFSEP (SV and ACG), Sana 
Kliniken (PF), University of Goettingen (OR and TM), Italian MS Society (GB and PZ) and University of 
Ferrara (MP). The registries, which had earlier responded in above mentioned surveys, were 
presented with a partly pre-filled form with their previous answers in order to facilitate their 
participation. They were instructed to review and update the pre-filled information. The registries, 
which had not participated in previous surveys, were sent a clean version of the survey.  
Reminders and follow up questions: The contact persons of each registry received at least one email 
reminder if they failed to respond the first time. Representatives of registries who completed the 
survey were re-approached regarding their availability for follow up questions. We interviewed nine 
of the registry representatives by phone, nine via email and one was interviewed in person. 
Interviews were aimed to further explore the registry-funding situation and how governance and 
involvement in scientific collaborations was regulated. There were also interview questions regarding 
missing information in the survey and potential overlaps with other registries.  
Analysis of the results: The results of the surveys were analysed and summarized. Due to missing 
data collection information, resulting in the total number of responding registries varying between 
16 and 19 (Tables 3-6), the results are presented as the number of registries collecting data 
compared to the total number of responding registries. 
 
Results:  
Nineteen MS registries agreed to participate in our survey (Table 1). Although we initially also 
approached MS registries outside Europe, all the registries which responded to our survey are based 
in Europe with the exception of MSBase which includes patient records from 33 countries and whose 
administrative offices are based in Australia (15). Most of the registries are national although there is 
at least one regional registry (Catalonia) (17, 18). In addition there is one national sub-group registry 
(DMSKW - a German pregnancy registry) (13). Four European or US MS registries did not reply or did 
not return the survey results.  
The results of the survey revealed that 10/18 (56%) of registries reported that an academic/research 
institution was keeping the registry followed by 4/18 (22%) kept by patient organisations and 3/18 
(17%) by health care organisations. Three registries were from “non-profit organisations” and one 
from “association of research centres”. One registry did not report organisation information and 
some of the registries reported more than one organisation keeping the registry (Table 1).  
The number of patients included in the participating MS registries covers a wide range, from around 
1000 to 50,000 PwMS. However, information about the prevalence of individual countries was not 
included in the present survey. There are known overlaps of patients between some of the registries 
but the extent of such overlaps is difficult to estimate. Some registries were started more than 50 
years ago and some very recent which might also reflect the size of the registries (Table 1). 
All the registries report that they include patients according to McDonald criteria, while 10 registries 
additionally include patients based on Poser criteria. Thirteen registries also include possible MS/CIS 
patients that are not fulfilling McDonald/Poser criteria, and four registries include patients with self-
reported MS without clinical validation. Seventeen registries reported including centres with any 
number of PwMS whilst one registry reported that a minimum number of MS patients within a 
centre is required in order to be included (Table 2).  
In the general categories of personal data, basic disease and treatments, data are collected by all 
registries (Table 3). Clinical  data on disability by Expanded Disability Status Scale (EDSS) is collected 
by 18 of the responding registries, whilst other disability measures are less frequently collected 
(Table 4). Cognition scales are only recorded by 9/19 (47%) of the registries (Table 3) where the most 
commonly reported scales are the Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial 
Addition Test (PASAT3), reported by 7/18 (39%) and 6/18 (33%) of the registries, respectively (Table 
4).  
Information on treatments was included in the survey for relapse therapy, disease modifying 
treatments (DMTs) and symptomatic treatments. Relapse therapy is collected by 15/18 (83%) of the 
registries. All registries reported data on DMTs, with 17/19 (89%) of the registries collecting data on 
current DMTs. Medical current symptomatic treatment is collected by 11/18 (61%) of the registries 
(Table 4).  
MRI data (yes or no) is reported by 16/19 (84%) of the registries, although the type of MRI data 
varies between registries and only 2/18 (11%) have reported collecting data on brain volume (Table 3 
and 4). 
Para-clinical data is collected by 14/19 (74%) of the registries and most frequently as information on 
cerebrospinal fluid (CSF) analysis of cells and intrathecal IgG production, which is collected by 13/19 
(68%) as well as evoked potentials/visual evoked potentials by 10/19 (52%) (Table 4).  
The number of registries that collect information on patient derived measures is generally lower than 
for the clinical categories. MS Impact Scale (MSIS-29) data is collected by 7/18 (39%) of the registries 
and represents, the most commonly collected outcome measure in this category. Information about 
depression is collected by 5/18 (28%) and fatigue by 6/19 (32%) of the registries. Fatigue is further 
explored in the survey by questions on six different fatigue scales but only two, Krupps’ Fatigue 
Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS) are reported to be recorded by any 
of the MS registries (Table 5).  
The survey also covered additional categories such as co-morbidities where chronic diseases and co-
medication were reported by 13/19 (68%) and 10/19 (53%) of the registries, respectively. There were 
also questions related to socio-economy included in our survey such as occupation, employment and 
education, recorded by 12/17 (71%), 14/19 (74%) and 12/19 (63%) of the registries, respectively. In 
addition, 6/18 (33%) of the registries reported collecting other socio-economic data (Table 6).  
Information on mandatory/optional data entries was provided by most of the registries at least for 
some categories. Data counts for a significant number of variables was provided by six registries 
(MSBase, OFSEP, MS-Register der DMSG (Bundesverband e.V.), the Italian MS Register, the Swedish 
Neuro Registries-MS and the UK MS Register). As this information was not provided by more 
registries, we have not incorporated this information in the results.   
The survey also included questions related to quality control strategies applied by the registries. 
Although only 10 registries specifically reported having a manual and/or automatic quality control 
mechanism, all registries except one, reported using some quality control system. Ten registries  
reported control of coverage of data-supplying centres and  10 registries reported control of 
representativeness of the population within the centres. The most common trigger for data entry 
was “Patient visit in data-supplying centre” which was reported by 15 registries (Table 7).  
The results from the questions regarding funding showed that five registries reported receiving 
public funding, whilst seven received support from industry. Non-profit funding was reported by 12 
registries and four reported other funding. Some registries reported more than one source of 
funding. Although five and 11 registries reported being very confident or fairly confident about 
future funding, four registries reported being not confident at all (Table 8a).   
Approval by data protection authorities and ethic committees had been required for 12 and 14 
registries, respectively. Informed consent was used by 16 registries and in 15 in the form of written 
informed consent. Access to data was regulated by all the 18 registries which responded to this 
survey question (Table 8a).  
We carried out follow up interviews mainly focused on funding and governance with all of the 19 MS 
registries, which in general confirmed the previous survey responses and provided further details 
especially regarding future funding and requirements needed to be met in order to carry out 
scientific collaborations. Although some, such as OFSEP, and the Danish and Italian MS registries, 
reported continued funding pending favourable evaluations on a regular basis, other registries had a 
less structured funding plan and two of the registries had no specific funding and were thus 
dependent on voluntary contributions. Scientific collaborations were generally welcomed by the MS 
registries but access to data for research purposes typically needed to be approved by local and/or 
national authorities (Table 8b).  
 
Discussion: 
The previous MS registry mapping survey from 2014 (14) was able to identify and describe the 
national MS registries in 13 European countries. With the present study, which includes 19 MS 
registries, we aim to give an informative and updated overview of the MS information currently 
collected in Europe. This could provide a useful basis towards further efforts at combining and 
harmonizing data from MS patients in order to carry out larger and statistically more powerful 
studies than what is possible on a national or local level. There are examples of international 
collaborations such as the European Register for Multiple Sclerosis (EUReMS) (14, 19) which was an 
EU funded collaboration of MS registries focussed on epidemiology and treatment studies and Big 
MS Data (BMSD) which is a collaborative effort, initiated in 2014, between OFSEP, the Danish, Italian  
and Swedish MS registries and MSBase. 
MS registries are often used in a clinical setting where registry data can assist the physician by 
making information on individual patients easily accessible. Such information can include data from 
access to health care services as well as a comprehensive overview of treatments, clinical procedures 
and other types of data about the patient. Many registries also focus on data which can be used for 
research purposes such as epidemiology, treatments effectiveness and safety and PROs. Patient 
derived measures have attracted increasingly more attention in the past few years, hence some of 
the registries are especially focussed on patient advocacy often involving an MS society or patient 
organisation. Patient organisations and MS societies report how MS patients often can and want to 
be involved in the management of their disease.  
The questions on socio-economy would likely be interpreted to refer to information directly available 
from the MS registries. This would therefore typically not include the way in which, in some 
countries, socio-economic information from public registries can be independently linked to data 
from patient registries as part of specific research projects requiring local ethics board approvals. s 
The reported information from MS registries in this report can provide a valuable description of 
potentially available data on a significant part of up to approximately 700,000 PwMS in Europe (20, 
21). Our study shows which categories of data are being collected but does not specify the number of 
data counts. The survey format did offer the possibility of reporting number of data counts per 
category but as many registries did not provide this information was not included in the summarized 
report. Furthermore, given the differences in the numbers of patients and the frequency of data 
collections, the amount and likely also the quality of collected data points varies significantly 
between registries and is difficult to estimate. For any potential future international collaboration, 
the issue of how to harmonise data from MS registries in the most optimal way with differences in 
patient inclusion criteria, collection frequency, quality control strategies and collected data 
categories as well as potential patient overlap between registries, will need to be given careful 
consideration. 
A mapping of the information that is collected by individual registries and their interest in and 
availability towards international collaborations is be a useful starting point for endeavours of 
combining and harmonizing large sets of data from MS patients. The BMSD project has managed to 
harmonise datasets from over 100.000 MS patients and the results are currently being analysed.  In 
addition to the growth of patient registries for scientific and clinical purposes, registries are receiving 
increased attention and support by MS Societies for their role in decision-making processes. Such 
long-term “real world evidence” data will also be of interest to pharmaceutical companies and 
regulatory bodies. However, any attempts at carrying out projects involving pooling large sets of data 
on MS patients or standardized analysis within the individual MS registries, will need to be carefully 
monitored and approved by both local and national authorities in order to ensure that data access 
and handling complies with national, international and ethical regulatory requirements.  
 
In conclusion, the number of MS patients in Europe is estimated at 500,000-700,000. We have 
identified 19 MS registries all based in Europe with the exception of the international MSBase and 
described the data collected by these registries that could provide a basis for the analysis of large 
amounts of data from MS patients.  
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